APOE variants are the largest monogenetic risk modifiers of Alzheimer's disease and have more recently been implicated in modulating additional phenotypes ranging from cardiovascular disease to tumor and infection immunity [31–35]. This evidence concerns the gene APOE and cardiovascular disorder.